GLP-1 Weight Loss Drugs Linked to Higher Alopecia Risk, Study Finds
The study provides the first solid evidence linking widely used weight loss drugs to hair loss, giving patients and doctors a new factor to weigh in treatment decisions.
Reporting from 1 source: GIGAZINE.
A University of Pennsylvania study compared over 50,000 type 2 diabetes patients and found GLP-1 receptor agonists like Ozempic and Mounjaro carry a 37% higher alopecia risk than SGLT2 inhibitors and 68% higher than DPP-4 inhibitors. The absolute risk remains low, with about 7 cases per 1,000 patients.
The study, published in The BMJ, used target trial emulation to compare patients who started GLP-1 receptor agonists with those on SGLT2 inhibitors and DPP-4 inhibitors. After adjusting for age, sex, ethnicity, and medical history, the association held. The research team noted that rapid weight loss has long been tied to hair loss, which may explain the effect. They stressed that the absolute risk is low but that awareness could inform treatment decisions.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.